Viagra-maker Pfizer is to acquire cancer drug company Medivation in a deal valued at about 14 billion US dollars (£10.6 billion).
Medivation is best known for cancer treatment Xtandi, which it jointly markets with Japanese drug maker Astellas Pharma.
Pfizer will pay 81.50 US dollars per Medivation share, which is a 21% premium on the biotech firm's closing price of 67.19 US dollars. The boards of both companies have approved the deal, which is expected to close in the third or fourth quarter.
Pfizer's Forfar-born chairman, Ian Read, said: "The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer.
"This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value."
Pfizer added that Medivation also has a promising pipeline of cancer drugs in late-stage clinical development, including the potential breast cancer treatment talazoparib and a lymphoma drug.
The deal comes last month after Medivation rejected a 9.3 billion US dollar takeover bid from the French drug maker Sanofi, saying that offer, worth 52.50 US dollars per share, undervalued the company.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here